<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777500</url>
  </required_header>
  <id_info>
    <org_study_id>2020P003800</org_study_id>
    <nct_id>NCT04777500</nct_id>
  </id_info>
  <brief_title>taVNS Treatment for Fibromyalgia</brief_title>
  <official_title>Applying Transcutaneous Auricular Vagus Nerve Stimulation to Treat Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study we want to learn more about if transcutaneous electrical nerve&#xD;
      stimulation (TENS), a safe electrical stimulation tool, can relieve Fibromyalgia pain. A&#xD;
      total of 60 subjects with Fibromyalgia will be enrolled in this study at Massachusetts&#xD;
      General Hospital, Charlestown Navy Yard campus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Revised Fibromyalgia Impact Questionnaire (FIQR)</measure>
    <time_frame>Baseline, week 2 and week 4.</time_frame>
    <description>A change in the FIQR would indicate that participants are experiencing pain relief.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS-29)</measure>
    <time_frame>Baseline, week 2 and week 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Catastrophizing Scale</measure>
    <time_frame>Baseline, week 2 and week 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory-II (BDI-II)</measure>
    <time_frame>Baseline and week 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Quantitative Sensory Testing (QST)</measure>
    <time_frame>Baseline and week 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>Baseline and week 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>power of oscillations in the alpha, theta, and gamma frequencies (optional)</measure>
    <time_frame>Baseline and week 4.</time_frame>
    <description>6 minutes of resting state EEG (with eyes open) (Optional). We will calculate the power of oscillations in the alpha, theta, and gamma frequencies, which will be normalized by the mean power for the global spectrum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood inflammation markers (optional)</measure>
    <time_frame>Baseline and week 4</time_frame>
    <description>We will examine inflammatory mediators such as interleukins (ILs including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, and IL-10), IFN-γ, and tumor necrosis factor (TNF) via multiplex immunoassays using Luminex, as well as highly sensitive C-reactive protein (hsCRP), programmed death 1 (PD-1), prostaglandin E2, and BDNF.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>taVNS Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive taVNS for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>taVNS Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive taVNS for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Auricular transcutaneous electrical nerve stimulation device</intervention_name>
    <description>We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.</description>
    <arm_group_label>taVNS Group 2</arm_group_label>
    <arm_group_label>taVNS Group1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet the American College of Rheumatology (ACR) 1990 classification criteria and the&#xD;
             ACR 2010 diagnostic criteria for fibromyalgia as determined by clinicians.&#xD;
&#xD;
          -  Willingness to complete a 4-week, twice-a-day treatments.&#xD;
&#xD;
          -  At least a 10th grade English-reading level; English can be a second language provided&#xD;
             that the patients understand all questions used in the assessment measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with medical conditions that are known to contribute to fibromyalgia&#xD;
             symptomatology, such as thyroid disease, inflammatory arthritis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, myositis, vasculitis, or Sjogren's syndrome.&#xD;
&#xD;
          -  History of cardiac, respiratory, or nervous system disease that, in the investigator's&#xD;
             judgment, precludes participation in the study because of a heightened potential for&#xD;
             adverse outcome. For example: asthma or claustrophobia.&#xD;
&#xD;
          -  Personal history of medical or psychiatric illness as determined by investigator.&#xD;
&#xD;
          -  Pregnant or lactating.&#xD;
&#xD;
          -  Less than a 10th grade English-reading level; English can be a second language&#xD;
             provided that the patients understand all questions used in the assessment measures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Kong</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maya Eshel, BA</last_name>
    <phone>(617) 726-5004</phone>
    <email>meshel@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129-2020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Eshel</last_name>
      <email>meshel@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Dao</last_name>
      <email>rdao@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jian Kong</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>taVNS</keyword>
  <keyword>Pain</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Fibromyalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

